Bloomberg News (4/30, Larson) reports Merck & Co. issued a statement saying, a jury in a Federal court in Trenton, New Jersey, on Monday, “found in its favor in a trial over claims its Fosamax [alendronate sodium] osteoporosis treatment caused a woman's femur to fracture spontaneously while she was gardening.” The plaintiff, 58-year-old Bernadette Glynn, filed suit against Merck on allegations that the Whitehouse Station, New Jersey-based pharmaceutical company “was aware Fosamax might cause brittle bones and increase fracture risks years before” the treatment was released on the market. Yesterday's trial, which was the “first of about 3,300” similar, pending lawsuits against Merck, was considered to be a “bellwether” on what direction the remaining jury cases would likely sway.